Oren Gilad - 30 Jan 2026 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)

Role: President/CEO, Director
Signature: /s/ John P. Hamill, as Attorney-in-Fact
Issuer symbol: APRE
Transactions as of: 30 Jan 2026
Net transactions value: +$25,009
Form type: 4
Filing time: 02 Feb 2026, 16:08:08 UTC
Previous filing: 11 Dec 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Gilad Oren	President/CEO, Director	3805 OLD EASTON ROAD, DOYLESTOWN	/s/ John P. Hamill, as Attorney-in-Fact	02 Feb 2026	0001929300

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APRE	Common Stock	Purchase	$25,009	+28,100	+8.1%	$0.8900	373,720	30 Jan 2026	Direct	F2
holding	APRE	Common Stock						1,200	30 Jan 2026	By Daughter	F1
holding	APRE	Common Stock						600	30 Jan 2026	By Son	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APRE	Common Warrant	Purchase		+28,100			28,100	30 Jan 2026	Common Stock	28,100	$0.7650	Direct	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
F2	On January 28, 2026, the Issuer entered into a securities purchase agreement with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Person in a private placement, which closed on January 30, 2026, an aggregate of 28,100 shares of the Issuer's common stock (the "Shares") at a purchase price of $0.89 per Share. The Reporting Person also received accompanying common warrants (the "Common Warrants") to purchase up to an aggregate of 28,100 Shares.
F3	The Common Warrants are immediately exercisable, provided, that, the Common Warrants cannot be exercised to the extent that, upon giving effect to or immediately prior to such exercise, would cause either (i) the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates) would exceed 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise or (ii) the combined voting power of the Issuer's securities beneficially owned by such holder (together with its affiliates) would exceed 9.99% of the combined voting power of all of the Issuer's securities outstanding immediately after giving effect to the exercise.
F4	The Common Warrants will expire on or prior to 5:00 p.m. (New York City time) on the second year anniversary of the earlier of: (i) the effective date of the registration statement registering the underlying Shares of the Common Warrants and (ii) the date the Shares underlying the Common Warrants are eligible for sale under Rule 144 (assuming cashless exercise of the Common Warrants) without the requirement for the Issuer to be in compliance with the current public information required under Rule 144.